Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Balsa

Showing results (1-10 of 246) with videos related to

Pageof 25
Sort By:
Reumatologia Clinica|July 29, 2011
[How do we evaluate an inadequate response in a patient with rheumaoid arthritis in the clinical praxis P?]Alejandro Balsa
Reumatologia Clinica|July 29, 2011
[Defining remission in Rheumatoid Arthritis. New ACR/EULAR criteria]Alejandro Balsa
Annals of the Rheumatic Diseases|January 8, 2018
Adalimumab concentration-based tapering strategy: as good as the recommended dosageDenis Mulleman, Alejandro Balsa
Rheumatic Diseases Clinics of North America|June 2, 2009
Infectious complications of biologic agentsEmilio Martin-Mola, Alejandro Balsa
Drugs & Aging|September 14, 2022
Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing PatientsMarta Novella-Navarro, Alejandro Balsa
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?Alejandro Balsa, Miriam García-Arias
Reumatologia Clinica|July 29, 2011
[Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis?]Virginia Villaverde García, Alejandro Balsa Criado
Reumatologia Clinica|June 11, 2013
Reply to: «understanding the immunogenicity concept»Alejandro Balsa, Chamaida Plasencia, Dora Pascual-Salcedo
Medicina Clinica|June 1, 2007
[Antibodies to citrullinated peptides in rheumathoid arthritis]Alejandro Balsa, Dora Pascual-Salcedo, Javier Martín
Reumatologia Clinica|January 14, 2026
Clinical practice guidelines for the management of patients with rheumatoid arthritis. GUIPCAR 2025Alejandro Balsa, Petra Díaz Del Campo Fontecha,
Pageof 25

Showing results (1-10 of 246) with videos related to

Sort By:
Pageof 25
Reumatologia Clinica|July 29, 2011
[How do we evaluate an inadequate response in a patient with rheumaoid arthritis in the clinical praxis P?]Alejandro Balsa
Reumatologia Clinica|July 29, 2011
[Defining remission in Rheumatoid Arthritis. New ACR/EULAR criteria]Alejandro Balsa
Annals of the Rheumatic Diseases|January 8, 2018
Adalimumab concentration-based tapering strategy: as good as the recommended dosageDenis Mulleman, Alejandro Balsa
Rheumatic Diseases Clinics of North America|June 2, 2009
Infectious complications of biologic agentsEmilio Martin-Mola, Alejandro Balsa
Drugs & Aging|September 14, 2022
Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing PatientsMarta Novella-Navarro, Alejandro Balsa
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?Alejandro Balsa, Miriam García-Arias
Reumatologia Clinica|July 29, 2011
[Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis?]Virginia Villaverde García, Alejandro Balsa Criado
Reumatologia Clinica|June 11, 2013
Reply to: «understanding the immunogenicity concept»Alejandro Balsa, Chamaida Plasencia, Dora Pascual-Salcedo
Medicina Clinica|June 1, 2007
[Antibodies to citrullinated peptides in rheumathoid arthritis]Alejandro Balsa, Dora Pascual-Salcedo, Javier Martín
Reumatologia Clinica|January 14, 2026
Clinical practice guidelines for the management of patients with rheumatoid arthritis. GUIPCAR 2025Alejandro Balsa, Petra Díaz Del Campo Fontecha,
Pageof 25